We are live on
!
Find out more
Spyre Therapeutics
SYRE
SYRE
197 hedge funds and large institutions have $4.16B invested in Spyre Therapeutics in 2026 Q1 according to their latest regulatory filings, with 58 funds opening new positions, 66 increasing their positions, 49 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
952% more call options, than puts
Call options by funds: $16.4M | Put options by funds: $1.55M
427% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 11
67% more funds holding in top 10
Funds holding in top 10: 6 → 10 (+4)
57% more capital invested
Capital invested by funds: $2.65B → $4.16B (+$1.51B)
35% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 49
29% more funds holding
Funds holding: 153 → 197 (+44)
0.87% more ownership
Funds ownership: 104.36% → 105.23% (+0.87%)
Holders
197
Holders Change
+44
Holders Change %
+28.76%
% of All Funds
2.42%
Holding in Top 10
10
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+66.67%
% of All Funds
0.12%
New
58
Increased
66
Reduced
49
Closed
11
Calls
$16.4M
Puts
$1.55M
Net Calls
+$14.8M
Net Calls Change
+$2.4M
Top Buyers
| 1 |
JP Morgan Chase
New York
|
+$34.5M |
| 2 |
CP
Caligan Partners
New York
|
+$33.1M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$30.5M |
| 4 |
PA
Perceptive Advisors
New York
|
+$26.9M |
| 5 |
PBA
Paradigm Biocapital Advisors
New York
|
+$18.5M |
Top Sellers
| 1 |
Capital International Investors
Los Angeles,
California
|
-$65.8M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
-$26.5M |
| 3 |
DM
Deerfield Management
New York
|
-$23.3M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$21.7M |
| 5 |
CC
Commodore Capital
New York
|
-$17.9M |
